457628-14-7

Usage

Uses

6-Fluoro-2,3-dimethoxybenzaldehyde is used for chemical research.

Upstream product

• 398-62-9 4-fluoroveratrole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1027984-78-6 1-Fluoro-3,4-dimethoxy-2-((E)-2-nitro-vinyl)-benzene 
• 1364684-49-0 3-(3-benzyloxy-propoxy)-6-fluoro-2-hydroxy-benzaldehyde 
• 1364684-57-0 trifluoro-methanesulfonic acid 6-(3-benzyloxy-propoxy)-3-fluoro-2-formyl-phenyl ester 
• 1364684-63-8 3-(3-benzyloxy-propoxy)-6-fluoro-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzaldehyde 
• 1364684-69-4 7-(3-benzyloxy-propoxy)-4-fluoro-3-nitromethyl-3H-benzo[c][1,2]oxaborol-1-ol 
• 1364684-82-1 3-ethoxy-6-fluoro-2-hydroxy-benzaldehyde 
• 1364684-90-1 trifluoro-methanesulfonic acid 6-ethoxy-3-fluoro-2-formyl-phenyl ester 
• 1364684-98-9 3-ethoxy-6-fluoro-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzaldehyde 
• 1364684-42-3 6-fluoro-2,3-dihydroxy-benzaldehyde 
• 457628-15-8 6-fluoro-2-hydroxy-3-methoxybenzaldehyde 
• 181305-45-3 1-(5-Bromo-pyridin-2-yl)-3-[2-(6-fluoro-2,3-dimethoxy-phenyl)-ethyl]-thiourea 
• 1027429-39-5 2,3-dimethoxy-6-fluorophenethylamine 

Relevant academic research and scientific papers

BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS

The present invention relates to benzofurane and benzothiophene derivatives of formula (I) Formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

BORON-CONTAINING SMALL MOLECULES

This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.

ACYCLIC IKUR INHIBITORS

A compound of formula I wherein R1, R2, R3, R4 and R5 are described herein.

Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs

Phenylethylthiazolylthiourea (PETT) derivatives have been identified as a new series of nonnucleoside inhibitors of HIV-1 RT. Structure-activity relationship studies of this class of compounds resulted in the identification of N-[2-(2-pyridyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea hydrochloride (trovirdine; LY300046.HCl) as a highly potent anti-HIV-1 agent. Trovirdine is currently in phase one clinical trials for potential use in the treatment of AIDS. Extension of these structure-activity relationship studies to identify additional compounds in this series with improved properties is ongoing. A part of this work is described here. Replacement of the two aromatic moleties of the PETT compounds by various substituted or unsubstituted heteroaromatic rings was investigated. In addition, the effects of multiple substitution in the phenyl ring were also studied. The antiviral activities were determined on wild-type and constructed mutants of HIV-1 RT and on wild-type HIV-1 and mutant viruses derived thereof, Ile100 and Cys181, in cell culture assays. Some selected compounds were determined on double- mutant viruses, HIV-1 (Ile100/Asn103) and HIV-1 (Ile100/Cys181). A number of highly potent analogs were synthesized. These compounds displayed IC50's against wild-type RT between 0.6 and 5 nM. In cell culture, these agents inhibited wild-type HIV-1 with ED50's between I and 5 nM in MT-4 cells. In addition, these derivatives inhibited mutant HIV-1 RT (Ile 100) with IC50's between 20 and 50 nM and mutant HIV-1 RT (Cys 181) with IC50's between 4 and 10 nM, and in cell culture they inhibited mutant HIV-1 (Ile100) with ED50's between 9 and 100 nM and mutant HIV-1 (Cys181) with ED50's between 3 and 20 nM.